Parallel Advisors LLC Lowers Holdings in Novo Nordisk A/S (NYSE:NVO)

Parallel Advisors LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 6.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,119 shares of the company’s stock after selling 3,268 shares during the period. Parallel Advisors LLC’s holdings in Novo Nordisk A/S were worth $4,139,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in the business. GWN Securities Inc. purchased a new stake in shares of Novo Nordisk A/S in the fourth quarter worth about $268,000. Glenview Trust co lifted its position in shares of Novo Nordisk A/S by 55.8% in the fourth quarter. Glenview Trust co now owns 20,566 shares of the company’s stock worth $1,769,000 after buying an additional 7,369 shares in the last quarter. Patten & Patten Inc. TN lifted its position in shares of Novo Nordisk A/S by 480.5% in the fourth quarter. Patten & Patten Inc. TN now owns 21,855 shares of the company’s stock worth $1,880,000 after buying an additional 18,090 shares in the last quarter. Hutchinson Capital Management CA lifted its position in shares of Novo Nordisk A/S by 0.3% in the fourth quarter. Hutchinson Capital Management CA now owns 175,651 shares of the company’s stock worth $15,109,000 after buying an additional 563 shares in the last quarter. Finally, Avalon Trust Co lifted its position in shares of Novo Nordisk A/S by 29.0% in the fourth quarter. Avalon Trust Co now owns 3,061 shares of the company’s stock worth $263,000 after buying an additional 689 shares in the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NVO. Stifel Nicolaus downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Up 4.0 %

NVO opened at $80.26 on Tuesday. The stock has a market cap of $360.15 billion, a price-to-earnings ratio of 24.39, a P/E/G ratio of 0.90 and a beta of 0.42. The stock’s 50 day moving average price is $83.85 and its 200-day moving average price is $102.39. Novo Nordisk A/S has a one year low of $73.80 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.